Herranz Pedro, Morton Colin, Dirschka Thomas, Azeredo Rosario Rodríguez, Roldán-Marín Rodrigo
Department of Dermatology, La Paz University Hospital, Madrid, Spain
Forth Valley Dermatology Centre, Stirling Community Hospital, NHS Forth Valley, Stirling, UK.
J Cutan Med Surg. 2016 Nov;20(6):555-561. doi: 10.1177/1203475416659259. Epub 2016 Jul 21.
Actinic keratosis (AK) lesions have the potential to develop into invasive squamous cell carcinomas (SCCs), and approaches to treatment are evolving to try to reduce the burden of SCC.
To present the published clinical research surrounding the use of 0.5% 5-fluorouracil with 10% salicylic acid (low-dose 5-FU/SA) for the treatment of hyperkeratotic AKs.
A review of published clinical evidence for low-dose 5-FU/SA for the treatment of AKs. The articles were selected following a MEDLINE database search of the combined terms fluorouracil, salicylic acid and actinic keratosis which represent the peer review publications of clinical studies that primarily investigate the use of Actikerall in AK.
Combining low-dose 5-FU with keratolytic SA is associated with high rates of histologic clearance, reduction in lesion number/area, and sustained clinical response in clinical study and the clinical practice setting. Low-dose 5-FU/SA has also been evaluated using imaging to detect the progression of subclinical AK lesions through a course of the field-directed treatment.
Low-dose 5-FU/SA is an effective and well-tolerated treatment option licensed for the lesion-directed treatment of mild-to-moderate hyperkeratotic AK lesions.
光化性角化病(AK)皮损有发展为浸润性鳞状细胞癌(SCC)的可能,治疗方法也在不断演变,以试图减轻SCC的负担。
介绍已发表的关于使用0.5% 5-氟尿嘧啶与10%水杨酸(低剂量5-FU/SA)治疗角化过度型AK的临床研究。
对已发表的低剂量5-FU/SA治疗AK的临床证据进行综述。文章是在MEDLINE数据库中搜索氟尿嘧啶、水杨酸和光化性角化病的组合术语后挑选出来的,这些术语代表了主要研究在AK中使用Actikerall的临床研究的同行评审出版物。
在临床研究和临床实践中,低剂量5-FU与角质溶解剂SA联合使用与高组织学清除率、皮损数量/面积减少以及持续的临床反应相关。低剂量5-FU/SA也已通过影像学评估,以检测在整个区域定向治疗过程中亚临床AK皮损的进展情况。
低剂量5-FU/SA是一种有效且耐受性良好的治疗选择,已获许可用于轻度至中度角化过度型AK皮损的靶向治疗。